Advanced Biomed Inc. Common Stock
ADVB
NASDAQ Global Select4.39
USD
-0.02
- -
CIK
0001941029
ISIN
US00752P2039
CUSIP
00752P203
Return %
Stock
S&P500
1Y
-78.05
26.53
3Y
-93.99
76.60
5Y
-93.99
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Yi Lu
- Full Time Employees
- 40
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 122 East 42nd Street New York City NY United States of America 10168
- IPO Date
- Mar 6, 2025
- CIK
- 0001941029
- Website
- advanbiomed.com
- Similar Companies
- Business
- Advanced Biomed Inc is a biotechnology holding company primarily engaged in the research and development of original microfluidic biochip technologies for precision oncology. The company develops and commercializes assay products and services that support early cancer screening and detection, diagnosis, staging, treatment selection, and patient outcome interventions using a proprietary microfluidic platform that integrates semiconductor technology and biotechnology. Its core products include devices such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, along with corresponding microfluidic biochips namely the A+Pre Chip, AC-1000 CTC Enrichment Chip, and A+CellScan Chip, designed to provide rapid and affordable cancer diagnostic solutions. Additionally, Advanced Biomed offers immunostaining kits A+CTCE, A+CTCM, A+EMT, and A+CM to determine and identify protein expressions and cell types, as well as the A+LCGuard Lung Cancer Early Screening Kit. The company operates through subsidiaries in Taiwan, Hong Kong, and Mainland China, with its holding company incorporated in Nevada and headquarters in Tainan, Taiwan. Founded in 2014, Advanced Biomed targets oncology and biomedical sectors with a focus on precision medicine and advanced diagnostics. In recent developments, Advanced Biomed launched the A+PerfusC system, an integrated perfusion 3D cell culture platform designed to replicate human physiological conditions in vitro for precision medicine and drug discovery applications. This system supports high-throughput drug screening by providing long-term cell culture with enhanced viability and growth, aiming to accelerate tumor profiling and personalized treatment developments. The launch of A+PerfusC represents a strategic expansion into 3D cell culture technology and personalized oncology testing platforms, positioning the company at the forefront of next-generation biomedical innovation. The company has also made regulatory progress and plans further global commercialization of its diagnostic devices and biochips, reflecting a key operational focus in 2024 and 2025 to scale manufacturing and global market reach. Advanced Biomed operates principally in the Asia-Pacific region, with ongoing efforts to advance regulatory approvals and extend its technology applications for cancer diagnostics and precision treatments. The company has not yet commenced significant product sales or revenue but continues to align its R&D efforts and product development with expanding clinical and market needs. Its strategic shift toward integrated biochip platforms and advanced 3D cell culture systems marks a major operational advancement within the last two years. Advanced Biomed’s business segments include biotechnology, healthcare diagnostics, and precision medicine. It is recognized for integrating microfluidic technology with semiconductor and biotechnology techniques to address cancer detection and treatment challenges, serving healthcare providers, research institutions, and pharmaceutical partners across its geographic footprint. This detailed corporate profile reflects Advanced Biomed Inc’s current product portfolio, strategic innovations, geographic scope, and recent operational expansions as of late 2025.
Advanced Biomed Inc. Announces 1 for 20 Share Consolidation
Reviewing Advanced Biomed (NASDAQ:ADVB) & Billiontoone (NASDAQ:BLLN)
Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary
Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering
IPO Update: Advanced Biomed Finalizes $112 Million U.S. IPO Plan
Advanced Biomed sets IPO terms, which could value the biotech at up to $625 million
Advanced Biomed Begins $150 Million U.S. IPO Rollout
Advanced Biomed to raise $150M in IPO